Section - CAP Smart Takes

02. Viloxazine Effect on Learning and School Problems in Youth With ADHD

Published on February 1, 2023 Certification expiration date: February 1, 2029

David R. Rosenberg, M.D.

Chair of the Department of Psychiatry & Behavioral Neuroscience - Wayne State University School of Medicine

Key Points

Learning and school problems can significantly impact long-term functioning, academic achievement, and overall health and well-being.
This post hoc analysis showed that viloxazine ER significantly reduced school and learning problems in children and adolescents with ADHD.

To unlock this audio you need to become a Silver, Gold, Silver extended or Gold extended Member.

Check Our CME Program

Downloads for Offline Access

Download Audio File (MP3)

Text version

Hi! David Rosenberg here for the Psychopharmacology Institute. In this CAP—or Child and Adolescent Psychiatry—Smart Take, we will look at the most recently FDA-approved nonstimulant medication, viloxazine ER or Qelbree, and its effect on learning and school problems in children with ADHD. It is an attractive nonstimulant alternative in the medication armamentarium for ADHD, especially since the response to viloxazine ER at week 6 can be predicted after only 2 weeks of treatment. Moreover, we know that learning and school problems are widespread in ADHD, and they significantly impact long-term functioning, academic achievement, and overall health and well-being.

So, although clinical symptom relief is essential, the overall level of functioning can be improved with improvement in academics, school, and learning problems. So, this report by Faraone is quite timely, and they found that viloxazine ER significantly reduced school and learning problems in children and adolescents with ADHD. What was especially

Unlock this CAP Smart Take and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.

Get Instant Access

Already have an account? Sign in

Next Section

03. Psychotropic Prescriptions in Youth During COVID-19 Pandemic

Learning Objectives:

Recognize that pharmacologic and nonpharmacologic interventions have large beneficial effects when combined.
Identify that viloxazine ER can significantly reduce learning and school problems and clinical ADHD symptoms.
Acknowledge that antipsychotic and antidepressant prescriptions remained high in September 2020 and had not decreased or returned to prepandemic levels.
Understand that lisdexamfetamine was well tolerated in preschool children with ADHD, with no new safety signals observed.
Recognize that a web-based pediatric drug information system can help prevent prescribing errors.

Original Release Date: February 1, 2023

Review and Re-release Date: February 1, 2026

Expiration Date: February 1, 2029

Expert: David Rosenberg, M.D.

Relevant Financial Disclosures:

None of the faculty, planners, and reviewers for this educational activity have relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.